Form D · Biotechnology
LikeMinds, Inc./DE
Boston, MA · CIK 0001753658
Offering snapshot reported Jun 14, 2021 · SEC filing
- Reported sold
- $1.15M Offering amount: $1.15M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 14, 2021 | Initial | $1,146,042 | No comparison | Not reported | SEC filing |
| Sep 20, 2018 | Initial | $5,222,671 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-402731
Source: Form D, filed Jun 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Henry Brem | Director |
| Gary Frashier | Director |
| Robert Langer | Director |
| Kenneth Rice | Executive |
| Peter G. Savas | Director, Executive |
| Paul Sekhri | Director |
| Robert Van Nostrand | Director |
| Vicki Zikopoulou | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
361 Newbury Street 5th Floor
Boston, MA, 02115
Boston, MA, 02115